Last reviewed · How we verify

NCT04021238

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

Completed Phase 2 Results posted Last updated 13 November 2023
What this trial tests

Phase 2 trial testing Perflutren lipid microsphere in Kidney Cancer in 25 participants. Completed in 5 August 2022.

Timeline
7 October 2020
Primary endpoint
5 August 2022
5 August 2022

Quick facts

Lead sponsorUNC Lineberger Comprehensive Cancer Center
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment25
Start date7 October 2020
Primary completion5 August 2022
Estimated completion5 August 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

UNC Lineberger Comprehensive Cancer Center — full company profile →

Who can join

Adults 18 to 99, any sex, with Kidney Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

3D CEUS Generated Metrics in Kidney Mass: Wash_In_Slope Primary · Baseline- up to 3 minutes

A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) Wash\_In\_Slope parameter was generated. This metric indicates the change in contrast with time in the mass using bolus imaging. Bolus imaging injects a small amount of contrast agent and monitors the contrast agent as it flows in (wash-in) and out (wash-out) of the body/mass. The intensity of the signal (the brightness of the image) is plotted over time to generate the time-intensity curve. The intensity of the signal (the brightness of the image) values range between 0=black, and 255=W

GroupValue95% CI
CEUS Imaging Parameters7.603.13 – 12.28
3D CEUS Generated Metric in Kidney Mass: Wash_In_intercept Primary · Baseline- up to 3 minutes

A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) Wash\_In\_intercept parameter was generated. This metric indicates the intensity level prior to infusion of contrast. The intensity of the signal (the brightness of the image) values range between 0=black, and 255=white. This value was calculated using an equation for a line which has a slope and the intercept. The values were negative because they were calculated (not measured).

GroupValue95% CI
CEUS Imaging Parameters-18.30-149.6 – 62.11
3D CEUS Generated Metric in Kidney Mass: Wash_Out_Slope Primary · Baseline- up to 3 minutes

A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) Wash\_Out\_Slope parameter was generated. This metric indicates the change in contrast with time in the mass using bolus imaging. Bolus imaging injects a small amount of contrast agent and monitors the contrast agent as it flows in (wash-in) and out (wash-out) of the body/mass. The intensity of the signal (the brightness of the image) is plotted over time to generate the time-intensity curve. The intensity of the signal (the brightness of the image) value range was between 0=black and 25

GroupValue95% CI
CEUS Imaging Parameters-0.93-2.09 – -0.41
3D CEUS Generated Metric in Kidney Mass: Wash_Out_Intercept Primary · Baseline- up to 3 minutes

A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) Wash\_Out\_Intercept parameter was generated. This metric indicates the intensity level of contrast at a steady state of enhancement in the mass. The intensity of the signal (the brightness of the image) values range between 0=black, and 255=White. This value was calculated using an equation for a line that has a slope and an intercept.

GroupValue95% CI
CEUS Imaging Parameters125.8443.28 – 199.71
3D CEUS Generated Metric in Kidney Mass: FR_a Primary · Baseline- up to 3 minutes

A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) FR\_a parameter was generated. The intensity of the signal (the brightness of the image) value range is between 0=black, and 255=white. The intensity was plotted by time. FR\_a parameters were devised from an exponential fit. The exponential fit of the data provides the height of the curve.

GroupValue95% CI
CEUS Imaging Parameters102.8461.01 – 152.8
3D CEUS Generated Metric in Kidney Mass: FR_beta Primary · Baseline- up to 3 minutes

A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) FR\_beta parameter was generated. The intensity of the signal (the brightness of the image) value range is between 0=black, 255=White. The intensity was plotted by time. FR\_beta parameters were devised from an exponential fit. Exponential fit of the data provides the slope of the curve.

GroupValue95% CI
CEUS Imaging Parameters0.160.03 – 0.77
3D CEUS Generated Metric in Kidney Mass: Volume Primary · Baseline- up to 3 minutes

A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) volume parameter was generated. The volumes were generated using the ellipsoid equation on the CEUS image of the kidney mass.

GroupValue95% CI
CEUS Imaging Parameters60.803.08 – 271.97
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. Wash_In_Slope Primary · Baseline- up to 3 minutes

The association between tumor pathology type (Clear cell renal carcinoma (CCRCC) versus none (CCRCC) pathology) and CEUS-generated Wash\_In\_Slope parameter was studied. This metric indicates the change in contrast intensity with time in the mass using bolus imaging. The intensity of the signal (the brightness of the image) values range between 0=black, and 255=White. The Wash\_In\_Slope increases as the contrast agent is introduced to the body/mass. This value was generated by fitting the data to a linear equation. Increasing brightness is related to the slope of the curve.

GroupValue95% CI
Clear Cell Renal Carcinoma7.61± 2.33
Papillary Carcinoma3.13± NA
Clear Cell Papillary4.23± NA
Chromophobe10.56± NA
Other12.28± NA
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. Wash_In_intercept Primary · Baseline- up to 3 minutes

The association between tumor pathology type (Clear cell renal carcinoma (CCRCC) versus none (CCRCC) pathology) and CEUS-generated Wash\_In\_intercept parameter was studied. This metric indicates the intensity level prior to infusion of contrast. The intensity of the signal (the brightness of the image) value range is between 0=black, and 255=White. This value was calculated using an equation for a line which has a slope and the intercept. The values were negative because they were calculated (not measured).

GroupValue95% CI
Clear Cell Renal Carcinoma-11.02± 58.96
Papillary Carcinoma-1.07± NA
Clear Cell Papillary31.12± NA
Chromophobe-53.10± NA
Other-122.88± NA
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. Wash_Out_Slope Primary · Baseline- up to 3 minutes

The association between tumor pathology type (Clear cell renal carcinoma (CCRCC) versus none (CCRCC) pathology) and CEUS-generated Wash\_Out\_Slope parameter was studied. This metric indicates the change in contrast intensity with time in the mass using bolus imaging. The intensity of the signal (the brightness of the image) value range is between 0=black, and 255=White. Decreasing brightness is related to the slope of the curve. The Wash Out slope decreases as the contrast agent clears the body/mass. Decreasing brightness is related to the slope of the curve. This results in a negative number

GroupValue95% CI
Clear Cell Renal Carcinoma7.62± 2.33
Papillary Carcinoma3.13± NA
Clear Cell Papillary4.23± NA
Chromophobe10.56± NA
Other12.3± NA
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. Wash_Out_Intercept Primary · Baseline- up to 3 minutes

The association between tumor pathology type (Clear cell renal carcinoma (CCRCC) versus none (CCRCC) pathology) and CEUS-generated Wash\_Out\_Intercept parameter was studied. This metric indicates the intensity level of contrast at steady state of enhancement in the mass. The contrast-enhanced ultrasonogram (CEUS) Wash\_Out\_Intercept parameter was generated. The intensity of the signal (the brightness of the image) value range is between 0=black, and 255=White. This value was calculated using an equation for a line which has a slope and the intercept.

GroupValue95% CI
Clear Cell Renal Carcinoma137.95± 36.88
Papillary Carcinoma-0.43± NA
Clear Cell Papillary118.53± NA
Chromophobe139.01± NA
Other148.49± NA
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. FR_a Primary · Baseline- up to 3 minutes

The association between tumor pathology type (Clear cell renal carcinoma (CCRCC) versus none (CCRCC) pathology) and CEUS-generated FR\_a parameter was studied. The intensity of the signal (the brightness of the image) values range between 0=black, and 255=White. The intensity was plotted by time. FR\_a parameters were devised from an exponential fit. The exponential fit of the data provides the height of the curve.

GroupValue95% CI
Clear Cell Renal Carcinoma105.34± 27.09
Papillary Carcinoma0± NA
Clear Cell Papillary0± NA
Chromophobe0± NA
Other0± NA

Sponsor's own description

The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with suspected kidney cancer with the same accuracy as conventional ultrasound and contrast-enhanced magnetic resonance imaging (MRI)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Perflutren lipid microsphere

Trials testing the same drug.

Other recruiting trials for Kidney Cancer

Currently open trials in the same condition.

Other UNC Lineberger Comprehensive Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04021238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing